$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000165731221000010 Filed on April 29, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.280M	$6.780M
YoY Change	36.87%	184.87%
% of Gross Profit
Research & Development	$13.57M	$7.622M
YoY Change	78.09%	-1.27%
% of Gross Profit
Depreciation & Amortization	$153.0K	$160.0K
YoY Change	-4.38%
% of Gross Profit
Operating Expenses	$22.86M	$14.48M
YoY Change	57.8%	43.41%
Operating Profit	-$22.86M	-$14.48M
YoY Change	57.8%
Interest Expense	$84.00K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	$1.646M	$2.189M
YoY Change	-24.81%	-5572.5%
Pretax Income	-$21.21M	-$12.30M
YoY Change	72.51%	40.51%
Income Tax	$80.00K	$51.00K
% Of Pretax Income
Net Earnings	-$21.29M	-$12.35M
YoY Change	72.44%	75.37%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.05	-$0.12
Diluted Earnings Per Share	-$0.05	-$0.12
COMMON SHARES
Basic Shares Outstanding	469.5M shares	105.5M shares
Diluted Shares Outstanding	469.5M shares	105.5M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$169.6M	$25.80M
YoY Change	557.36%	-63.35%
Cash & Equivalents	$169.6M	$24.98M
Short-Term Investments		$900.0K
Other Short-Term Assets	$1.484M	$2.400M
YoY Change	-38.17%	-25.0%
Inventory
Prepaid Expenses	$7.247M
Receivables
Other Receivables
Total Short-Term Assets	$188.6M	$39.00M
YoY Change	383.59%	-51.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$98.00K	$1.600M
YoY Change	-93.88%	300.0%
Goodwill	$545.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.549M	$5.500M
YoY Change	-71.84%	44.74%
TOTAL ASSETS
Total Short-Term Assets	$188.6M	$39.00M
Total Long-Term Assets	$1.549M	$5.500M
Total Assets	$190.2M	$44.50M
YoY Change	327.3%	-47.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$541.0K	$8.200M
YoY Change	-93.4%	30.16%
Accrued Expenses	$8.514M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$800.0K
YoY Change		166.67%
Total Short-Term Liabilities	$12.70M	$10.00M
YoY Change	26.98%	28.21%
LONG-TERM LIABILITIES
Long-Term Debt	$4.700M	$1.000M
YoY Change	370.0%
Other Long-Term Liabilities	$400.0K	$1.500M
YoY Change	-73.33%	0.0%
Total Long-Term Liabilities	$5.038M	$2.500M
YoY Change	101.52%	66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.70M	$10.00M
Total Long-Term Liabilities	$5.038M	$2.500M
Total Liabilities	$17.74M	$12.50M
YoY Change	41.89%	35.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$228.4M
YoY Change
Common Stock	$31.79M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.670M
YoY Change
Treasury Stock Shares
Shareholders Equity	$172.4M	$30.16M
YoY Change
Total Liabilities & Shareholders Equity	$190.2M	$44.50M
YoY Change	327.3%	-47.65%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$21.29M	-$12.35M
YoY Change	72.44%	75.37%
Depreciation, Depletion And Amortization	$153.0K	$160.0K
YoY Change	-4.38%
Cash From Operating Activities	-$18.55M	-$13.22M
YoY Change	40.28%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$5.000K
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	$0.00	$9.787M
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	$0.00
YoY Change
NET CHANGE
Cash From Operating Activities	-$18.55M	-$13.22M
Cash From Investing Activities	$0.00	$9.787M
Cash From Financing Activities	$0.00	$0.00
Net Change In Cash	-$18.39M	-$5.445M
YoY Change	237.7%
FREE CASH FLOW
Cash From Operating Activities	-$18.55M	-$13.22M
Capital Expenditures	$0.00	$5.000K
Free Cash Flow	-$18.55M	-$13.23M
YoY Change	40.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-38067
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	283 4200
CY2021Q1	dei	City Area Code CityAreaCode	203
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
CY2021Q1	dei	Entity Address Country EntityAddressCountry	GB
CY2021Q1	dei	Country Region CountryRegion	44
CY2021Q1	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
CY2021Q1	dei	Trading Symbol TradingSymbol	VRNA
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	463745750	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169598000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187986000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7247000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4538000	USD
CY2021Q1	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	10272000	USD
CY2020Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	8260000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1484000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1720000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	188601000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	202504000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	545000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	545000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	906000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1050000	USD
CY2021Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	1549000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1702000	USD
CY2021Q1	us-gaap	Assets Assets	190150000	USD
CY2020Q4	us-gaap	Assets Assets	204206000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	541000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	178000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8514000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10863000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	757000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	798000	USD
CY2021Q1	vrna	Warrant Liability Current WarrantLiabilityCurrent	2753000	USD
CY2020Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	2246000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	133000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	118000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12698000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14203000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4685000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4635000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	353000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	514000	USD
CY2021Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5038000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5149000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	17736000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	19352000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	488304446	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	488304446	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	463745750	shares
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	366411000	USD
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1670000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1700000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13574000	USD
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	463304446	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	31794000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	31794000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	375261000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228370000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-207050000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	172414000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	190150000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204206000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7622000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9282000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6862000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	22856000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	14484000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-22856000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14484000	USD
CY2021Q1	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	2070000	USD
CY2020Q1	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1685000	USD
CY2021Q1	us-gaap	Investment Income Net InvestmentIncomeNet	4000	USD
CY2020Q1	us-gaap	Investment Income Net InvestmentIncomeNet	69000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	84000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q1	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	-507000	USD
CY2020Q1	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	142000	USD
CY2021Q1	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	163000	USD
CY2020Q1	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	293000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1646000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2189000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21210000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12295000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	80000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12346000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2157000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21290000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14503000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	469465085	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	469465085	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105453364	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105453364	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8850000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	172414000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	42741000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12346000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2157000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	52000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1867000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	30157000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12346000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	155000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	234000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	19000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31000	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	507000	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-142000	USD
CY2021Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	USD
CY2020Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	289000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8850000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1867000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	153000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	160000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2709000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-195000	USD
CY2021Q1	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	2012000	USD
CY2020Q1	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	1632000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-236000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-845000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	716000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	363000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1106000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2349000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1343000	USD
CY2021Q1	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-210000	USD
CY2020Q1	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	575000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	15000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	364000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18551000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13224000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	9792000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9787000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2008000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18388000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5445000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30428000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	169598000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24983000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	55000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021Q1	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	2	subsidiary
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228400000	USD
CY2021Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	subsidiary
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	subsidiary
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation and the fair value of warrants. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2021Q1	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	6296000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7247000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4538000	USD
CY2020Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	2551000	USD
CY2021Q1	us-gaap	Prepaid Insurance PrepaidInsurance	574000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1701000	USD
CY2021Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	377000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	286000	USD
CY2021Q1	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	10272000	USD
CY2020Q4	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	8202000	USD
CY2021Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	58000	USD
CY2021Q1	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	10272000	USD
CY2020Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	8260000	USD
CY2021Q1	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	6536000	USD
CY2020Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	8607000	USD
CY2021Q1	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1454000	USD
CY2020Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2149000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	524000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	107000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8514000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10863000	USD
CY2020	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2021Q1	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2021Q1	vrna	Class Of Warrant Or Right Intrinsic Value ClassOfWarrantOrRightIntrinsicValue	0	USD
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2021Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y1M2D
CY2020Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y3M29D
CY2021Q1	vrna	Warrant Liability Current WarrantLiabilityCurrent	2753000	USD
CY2020Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	2246000	USD
CY2021Q1	vrna	Sensitivity Analysis Of Fair Value Warrant Liability Impact Of10 Percent Increase In Volatility Rate SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentIncreaseInVolatilityRate	3282000	USD
CY2021Q1	vrna	Warrant Liability Fair Value WarrantLiabilityFairValue	2753000	USD
CY2021Q1	vrna	Sensitivity Analysis Of Fair Value Warrant Liability Impact Of10 Percent Decrease In Volatility Rate SensitivityAnalysisOfFairValueWarrantLiabilityImpactOf10PercentDecreaseInVolatilityRate	2234000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4700000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8850000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1867000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13125672	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.41
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	996720	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.17
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12128952	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.43
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12346000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21290000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21290000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12346000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-12346000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	469465085	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	469465085	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105453364	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105453364	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	77584846	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35669750	shares

Files In Submission

Name	View Source	Status
0001657312-21-000010-index-headers.html	Edgar Link	pending
0001657312-21-000010-index.html	Edgar Link	pending
0001657312-21-000010.txt	Edgar Link	pending
0001657312-21-000010-xbrl.zip	Edgar Link	pending
exhibit311q121.htm	Edgar Link	pending
exhibit312q121.htm	Edgar Link	pending
exhibit321q121.htm	Edgar Link	pending
exhibit322q121.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20210331.htm	Edgar Link	pending
vrna-20210331.xsd	Edgar Link	pending
vrna-20210331_cal.xml	Edgar Link	unprocessable
vrna-20210331_def.xml	Edgar Link	unprocessable
vrna-20210331_htm.xml	Edgar Link	completed
vrna-20210331_lab.xml	Edgar Link	unprocessable
vrna-20210331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2021 Q1 Form 10-Q Financial Statement

#000165731221000010 Filed on April 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2021 Q1 Form 10-Q Financial Statement

#000165731221000010 Filed on April 29, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna